Home  >  Press Releases  >  Companion Animals
Share

Press Releases

Press release year list 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
April 19, 2022
First-of-its-kind, multi-purpose technology now offers artificial intelligence (AI) blood smear and fecal testing, along with digital cytology in a single platform, furthering company commitment to diagnostics that drive animal care PARSIPPANY, N.J. – April 19, 2022 – Zoetis today announced its latest innovation in diagnostics with the addition of artificial intelligence (AI) blood smear testing to its multi-purpose platform, Vetscan ImagystTM. Introduced in September 2020, Vetscan Imagyst is a first-of-its- kind technology with a multitude of applications, including AI fecal analysis, digital cytology image transfer and now AI blood smear – ultimately helping veterinarians broaden in-clinic diagnostic offerings to provide the best possible care for dogs and cats. The Vetscan Imagyst AI-driven blood smear capability efficiently delivers critical information that will assist veterinarians in making diagnoses of, and guiding treatment decisions for, animals who are sick or those with ...
January 10, 2022
A Convenient Solution to Rapidly and Safely Stop the Cycle of Pruritus in Allergic Dogs and Clinical Signs of Atopic Dermatitis in Dogs ZAVENTEM, BELGIUM, January 10, 2022 – Zoetis announced that the European Commission (EC) has granted the marketing authorization for Apoquel ® chewable tablets (oclacitinib) for dogs for the treatment of clinical manifestations of pruritus associated with allergic dermatitis in dogs and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. The Veterinary Medicines Directorate (VMD) marketing authorization for Great Britain (GB) was received on November 24 th , 2021. “The approval of Apoquel chewable tablets in the European Union provides a convenient new treatment choice for dogs that suffer from allergic skin conditions. This treatment affords an opportunity for the damaged skin to heal, while allowing the veterinarian ample time to identify ...
January 4, 2022
Simparica Trio proven to block the pathogen that causes Lyme disease by killing deer ticks PARSIPPANY, N.J. –January 4, 2022– Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio ® (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks (black-legged or deer ticks).  Simparica Trio is approved for dogs eight weeks of age and older weighing 2.8 pounds and greater. Simparica Trio is the first and only combination product demonstrated to prevent infections that may cause Lyme disease by killing deer or black-legged ticks. “Tick-borne diseases are a serious threat to pets and Lyme disease, caused by Borrelia burgdorferi , is transmitted by deer ticks. It is critical to have easily accessible and effective options for preventing infections available to protect dogs from ticks so ...